Section 5 of 6
Economic information and modeling report
42 evidence topics · 28 sources
Modeling overview
Summary
No budget impact model, cost-effectiveness analysis, or health technology assessment of ficerafusp alfa was found, and no price for it has been published. Bicara states that ficerafusp alfa “may be priced at a significant premium over competitive products if any have been approved by then”, and its presentation describes first-line recurrent or metastatic HPV-negative HNSCC as “a global commercial opportunity of ~$5B+ annually by 2030”. Three published U.S. payer models address first-line comparators. Borse et al. (2022) used a three-state partitioned-survival model over 20 years with 3% annual discounting: pembrolizumab monotherapy was dominant versus the EXTREME regimen in the CPS ≥1 population, and pembrolizumab combination therapy was cost-effective versus EXTREME at $1769/QALY in the overall population. In the Markov model of She et al. (2022), pembrolizumab plus chemotherapy versus cetuximab plus chemotherapy yielded ICERs of $147876.14, $134237.84, and $153660.78 per QALY in the total, CPS ≥1, and CPS ≥20 populations. Ye et al. (2024), using a 15-year three-state partitioned survival model, found the EXTREME regimen cost-effective compared with nivolumab plus ipilimumab at a willingness-to-pay threshold of $150,000/QALY. None of these models includes ficerafusp alfa.
Budget impact model, cost-effectiveness analysis, or health technology assessment of ficerafusp alfa
No evidence found.
Company statements on pricing and launch timing of ficerafusp alfa
Company estimate of the market for first-line treatment of recurrent or metastatic HPV-negative disease
Cost-effectiveness of first-line pembrolizumab regimens from a United States payer perspective
“Using public drug prices, from a US payer perspective, we evaluated the cost-effectiveness of each pembrolizumab regimen vs. cetuximab + platinum+5-FU (EXTREME regimen, trial comparator), cisplatin + docetaxel + cetuximab (TPEx regimen), cisplatin + paclitaxel, and platinum+5-FU.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“First-line pembrolizumab monotherapy in patients with CPS ≥1, and pembrolizumab combination therapy in the overall R/M HNSCC population is cost-effective from the perspective of the US payers.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cost-effectiveness of first-line pembrolizumab with or without chemotherapy versus cetuximab plus chemotherapy
“First-line treatment with pembrolizumab or pembrolizumab plus chemotherapy are cost-effective strategies compared with cetuximab plus chemotherapy when the value of willingness-to-pay (WTP) was $150000 per QALY for the total and PD-L1 CPS ≥ 1 populations with recurrent or metastatic HNSCC.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cost-effectiveness of first-line nivolumab plus ipilimumab versus the EXTREME regimen
“The EXTREME regimen is cost-effective compared with nivolumab plus ipilimumab for all randomly assigned populations with R/M SCCHN at a WTP threshold of $150,000/QALY from the payer's perspective in the United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Budget impact model
Approach and framework
Budget impact model of ficerafusp alfa: approach and framework
No evidence found.
Good-practice framework for budget impact analysis
“The key elements of a BIA include estimating the size of the eligible population, the current mix of treatments and the expected mix after the introduction of the new intervention, the cost of the treatment mixes, and any changes expected in condition-related costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Where possible, the BIA calculations should be performed by using a simple cost calculator approach because of its ease of use for budget holders.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In instances, however, in which the changes in eligible population size, disease severity mix, or treatment patterns cannot be credibly captured by using the cost calculator approach, a cohort or patient-level condition-specific model may be used to estimate the budget impact of the new intervention, accounting appropriately for those entering and leaving the eligible population over time.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Finally, the Task Force recommends that the analyst use the simplest design that will generate credible and transparent estimates.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The model should be consistent with that used for the CEA with regard to clinical and economic assumptions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Model structures used in economic evaluations of first-line regimens for recurrent or metastatic disease
“A three-state partitioned-survival model was used to project costs and outcomes over 20 years with 3% annual discounting.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Time-on-treatment was derived from KEYNOTE-048 or approximated using network meta-analysis progression-free survival estimates.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A Markov structure was conducted to evaluate the cost and effectiveness of pembrolizumab monotherapy or pembrolizumab plus chemotherapy vs. cetuximab plus chemotherapy in the first-line treatment of recurrent or metastatic HNSCC from the United States payer's perspective.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Perspective and time frame
Budget impact model of ficerafusp alfa: perspective and time frame
No evidence found.
Perspective recommended for budget impact analysis
Perspectives and time horizons of United States cost-effectiveness analyses of first-line regimens
“A three-state partitioned-survival model was used to project costs and outcomes over 20 years with 3% annual discounting.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The purpose of this study was to compare the cost-effectiveness of nivolumab plus ipilimumab with EXTREME in the first-line setting from the standpoint of third-party payers in the United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The projecting of costs and outcomes over 15 years was done using a three-state partitioned survival model discounted by 3% per year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The time horizon was 15 years given that more than 98% of the cohort died.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Epidemiology and eligible population inputs
Budget impact model of ficerafusp alfa: eligible population inputs
No evidence found.
Oral cavity and pharynx cancer incidence in the United States
Laryngeal cancer incidence in the United States
Share of head and neck cancer of squamous cell origin and share presenting with or progressing to recurrent or metastatic disease
Recurrence among older patients with locoregionally advanced disease in SEER-Medicare
“In the resected group (n = 502), 333 patients experienced recurrence and had a 63% increased risk of death vs nonrecurrent patients” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In those unresected (n = 1,217), 791 patients experienced recurrence and had a 77% increased risk of death” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Share of recurrent or metastatic disease that is HPV-negative
Share of oropharyngeal squamous cell carcinoma attributable to HPV in the United States
| Measure, oropharynx, 2012 to 2016 | Value |
|---|---|
| Reported HPV-associated cancers, average annual number | “19,000”View highlighted excerpt for this quote |
| Attributable to 9vHPV-targeted types, number (%) | “12,600 (66)”View highlighted excerpt for this quote |
| Attributable to other HPV types, number (%) | “900 (5)”View highlighted excerpt for this quote |
| HPV-negative, number (%) | “5,500 (29)”View highlighted excerpt for this quote |
HPV status and PD-L1 expression in the first-line pembrolizumab trial population
PD-L1 testing before first-line therapy in United States practice
First-line treatment mix and receipt of later lines in United States practice
“1410 patients (54.7%) were treated with anti-PD1 monotherapy, 577 (22.4%) with combination anti-PD1 plus chemotherapy, and 590 (22.9%) with cetuximab plus chemotherapy in the front-line setting for recurrent or metastatic disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Out of 2577 patients, 1128 patients (43.8%) were reported to have received second line treatment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Company estimate of newly diagnosed HPV-negative patients in the United States
Cost assumptions
Budget impact model of ficerafusp alfa: cost assumptions
No evidence found.
Ficerafusp alfa price
No evidence found.
Ficerafusp alfa dose and schedule in the pivotal trial
Pembrolizumab list price
Pembrolizumab dose and maximum treatment duration
Real-world time on first-line pembrolizumab treatment
“The median (95% CI) rwToT for the monotherapy group was 4.2 (3.5–4.6) months, while the median (95% CI) rwTTNT was 6.5 (5.4–7.4) months” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median rwToTs observed in the current study were also numerically similar to the corresponding median durations of study therapy observed in KEYNOTE-048 (4.2 versus 3.5 months for pembrolizumab monotherapy and 4.9 versus 5.8 months for pembrolizumab plus chemotherapy)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cetuximab list price
Cetuximab dose with chemotherapy
United States unit drug, administration, and terminal care costs used in a first-line cost-effectiveness model
| Input | Value (95% CI) |
|---|---|
| Nivolumab, drug cost per 1 mg, $ | “30 (29–32)”View highlighted excerpt for this quote |
| Cisplatin, drug cost per 1 mg, $ | “0.17 (0.14–0.2)”View highlighted excerpt for this quote |
| Carboplatin, drug cost per 1 mg, $ | “0.05 (0.04–0.06)”View highlighted excerpt for this quote |
| Fluorouracil, drug cost per 1 mg, $ | “0.005 (0.004–0.006)”View highlighted excerpt for this quote |
| Cetuximab, drug cost per 1 mg, $ | “7.04 (5.63–8.44)”View highlighted excerpt for this quote |
| Terminal care cost per patient, $ | “11,126 (8901–13,351)”View highlighted excerpt for this quote |
| Best supportive care cost per cycle, $ | “4645 (3716–5574)”View highlighted excerpt for this quote |
| Drug administration, first hour, $ | “150.34 (123.55–198.06)”View highlighted excerpt for this quote |
| Drug administration, additional hour, $ | “32.23 (27.29–41.02)”View highlighted excerpt for this quote |
Cost categories in a first-line cost-effectiveness model of pembrolizumab regimens
Incremental monthly health care costs associated with recurrence
Model outcomes
Budget impact model of ficerafusp alfa: model outcomes
No evidence found.
Outcomes recommended for budget impact analysis
“The outcomes of the BIA should be presented in the format of interest to health care decision makers.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In a computer program, options should be provided for different categories of costs to be included or excluded from the analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“If a health condition model is needed for the BIA, it should reflect health outcomes and their related costs in the total affected population for each year after the new intervention is introduced into clinical practice.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Outcomes reported by United States cost-effectiveness analyses of first-line regimens
“Total cost, health outcomes, and incremental cost-effective ratios (ICERs) were estimated.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Results
Base case
Budget impact model of ficerafusp alfa: base-case results
No evidence found.
Base-case results for first-line pembrolizumab regimens
“In the CPS ≥1 R/M HNSCC population, pembrolizumab monotherapy was dominant vs. EXTREME and TPEx regimens, and cost-effective (at $100,000/QALY threshold) vs. platinum+5-FU ($86,827/QALY) and cisplatin + paclitaxel ($81,473/QALY).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Pembrolizumab combination therapy in the overall R/M HNSCC population was dominant vs. TPEx regimen, and cost-effective vs. EXTREME regimen ($1769/QALY), platinum+5-FU ($81,989/QALY), and cisplatin + paclitaxel ($89,505/QALY).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Base-case results for first-line pembrolizumab with or without chemotherapy versus cetuximab plus chemotherapy
“When compared with cetuximab plus chemotherapy, the pembrolizumab monotherapy strategy was dominated by lower cost and better efficacy in all three populations.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The incremental costs and quality adjusted life years (QALYs) yielded by pembrolizumab plus chemotherapy compared with cetuximab plus chemotherapy were $16016.88 and 0.11 in the total population, and $24467.47 and 0.18 and $30448.46 and 0.20 in the populations with a PD-L1 CPS ≥ 1 and CPS ≥ 20, respectively, leading to ICERs of $147876.14, $134237.84, and $153660.78 per QALY, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Base-case results for first-line nivolumab plus ipilimumab versus the EXTREME regimen
Scenario analyses
Budget impact model of ficerafusp alfa: scenario analyses
No evidence found.
Scenario and sensitivity analyses recommended for budget impact analysis
Sensitivity analyses in United States cost-effectiveness analyses of first-line regimens
“Sensitivity analyses showed a high cost-effectiveness probability for pembrolizumab at the $100,000/QALY threshold.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Variations in HR for OS and body weight were generally the strongest influences on ICERs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Given a WTP threshold of $150,000 per QALY, the probability of the EXTREME regiment being cost-effective compared with nivolumab and ipilimumab, was 64%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Budget impact model discussion
Summary
Task force good-practice guidance on budget impact analysis lists the key elements of a budget impact analysis as the size of the eligible population, the current and expected treatment mix, the cost of each mix, and changes in condition-related costs, and recommends the perspective of the specific decision maker, data from the decision maker's own population where possible, and presentation as a series of scenario analyses. For ficerafusp alfa, two inputs are not yet available: a price, and efficacy from randomized evidence. Results reported to date come from a nonrandomized, open-label phase 1/1b trial, and Bicara expects an interim analysis of the randomized FORTIFI-HN01 trial in mid-2027.
The population inputs in this report differ by source and are candidates for scenario ranges. The estimated HPV-negative share of recurrent or metastatic disease is 80% in Bicara's Form 10-K; in a U.S. real-world first-line cohort, 60.4% had non-HPV associated disease and 7.0% had unknown HPV status or primary site, and in a U.S. real-world cohort of first-line pembrolizumab recipients, 258 participants (39.9%) were HPV-negative and 155 (24.0%) equivocal or unknown. Bicara states that up to 30% of patients develop a recurrence or metastases after initial treatment for advanced HNSCC; Hanna et al. (2026) state that approximately 50% of those with locally advanced HNSCC have recurrence or metastasis after initial therapy; of 2,207 U.S. participants, 32.7%. Because the pivotal population requires PD-L1 CPS ≥1, testing rates bear on the identifiable population: of 2,207 U.S. participants, 32.7% received PD-L1 testing before first-line therapy and 50.0% were never tested.
On costs, pembrolizumab is given in both arms of FORTIFI-HN01, and ficerafusp alfa is given weekly until disease progression or unacceptable toxicity, while pembrolizumab is given for up to 35 cycles. FORTIFI-FLEX is evaluating a 12-week loading phase of 1500 mg weekly followed by 2250 mg every 3 weeks, which would change the number of administrations if adopted. Bicara states that third-party payers “may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug or a less expensive therapy is available.”
Company statements on pricing, coverage, and reimbursement of ficerafusp alfa
Data sources recommended for budget impact inputs
“Data sources for the BIA should include published clinical trial estimates and comparator studies for the efficacy and safety of the current and new interventions as well as the decision maker's own population for the other parameter estimates, where possible.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote